China OKs Pfizer COVID drug
Subscribe to keep reading.
Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.
Already a subscriber? Log in.
On Friday, surprising news emerged from China's pharmaceutical regulator (NMPA):
Pfizer's COVID-19 treatment drug – Paxlovid – has received conditional approval to register in China.It's the first oral pill specifically developed for the disease to be cleared by regulators.
Business wheels ar...
Your subscription doesn't include access to this content. Upgrade your account to access.